-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, LIn5h8ecnWrfGhBfiCw/nzBS+8w9DfEUDkIZOlgq8mOzdK4g0hG8KBsh6xuqeJoP iqfbns1Ym2WvHbVXetM2Vw== 0001193125-10-028361.txt : 20100211 0001193125-10-028361.hdr.sgml : 20100211 20100211121245 ACCESSION NUMBER: 0001193125-10-028361 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20100211 DATE AS OF CHANGE: 20100211 GROUP MEMBERS: ABINGWORTH LLP SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: PONIARD PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000755806 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 911261311 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-40119 FILM NUMBER: 10590355 BUSINESS ADDRESS: STREET 1: 7000 SHORELINE COURT STREET 2: SUITE 270 CITY: SO. SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 2062862501 MAIL ADDRESS: STREET 1: 300 ELLIOTT AVENUE WEST STREET 2: SUITE 500 CITY: SEATTLE STATE: WA ZIP: 98119-4114 FORMER COMPANY: FORMER CONFORMED NAME: NEORX CORP DATE OF NAME CHANGE: 19920703 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Abingworth Management LTD CENTRAL INDEX KEY: 0001291892 IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 38 JERMYN STREET CITY: LONDON STATE: X0 ZIP: SW1Y 6DN BUSINESS PHONE: 44 20 7534 1508 MAIL ADDRESS: STREET 1: 38 JERMYN STREET CITY: LONDON STATE: X0 ZIP: SW1Y 6DN SC 13G/A 1 dsc13ga.htm SCHEDULE 13G AMENDMENT NO. 4 Schedule 13G Amendment No. 4
CUSIP No. 02043Q107    13G    Page 1 of 5

 

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO

RULES 13d-1 (b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO

RULE 13d-2(b)

(Amendment No. 4)*

 

 

Poniard Pharmaceuticals, Inc.

(Name of issuer)

 

 

Common Stock, $0.02 par value per share

(Title of class of securities)

732449301

(CUSIP number)

December 31, 2009

(Date of event which requires filing of this statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

x Rule 13d-1(c)

¨ Rule 13d-1(d)

 

*   The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

Item 1  

(a).

    Name of Issuer:      
     Poniard Pharmaceuticals, Inc., formerly NeoRx Corporation (the “Issuer”)      
Item 1  

(b).

    Address of Issuer’s Principal Executive Offices:      
    

7000 Shoreline Court, Suite 270

South San Francisco, CA 94080

      
Item 2  

(a).

    Name of Persons Filing:      
     Abingworth Management and Abingworth LLP. The foregoing individuals are each a “Reporting Person” and collectively referred to as the “Reporting Persons.”      
Item 2  

(b).

    Address of Principal Business Office or, if None, Residence:      
     The business address for each Reporting Person is Princes House, 38 Jermyn Street, London, England SW1Y 6DN.      
Item 2  

(c).

    Citizenship:      
     Abingworth Management is a corporation organized under the laws of England. Abingworth LLP is a limited liability partnership organized under the laws of England.      
Item 2  

(d).

    Title of Class of Securities:      
     Common Stock, $0.02 par value per share (the “Common Stock”)      
Item 2  

(e).

    CUSIP Number:      
     732449301      
Item 3   If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person filing is a:   
  Not applicable.   

Item 4.    Ownership.      
   Not applicable.      
Item 5.    Ownership of Five Percent or Less of a Class.   
   Each of the Reporting Persons has ceased to own beneficially five percent (5%) or more of the Issuer’s outstanding Common Stock.   
Item 6.    Ownership of More than Five Percent on Behalf of Another Person.      
   Not applicable.      
Item 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
   Not applicable.
Item 8.    Identification and Classification of Members of the Group.      
   Not applicable.      
Item 9.    Notice of Dissolution of Group.      
   Not applicable.      
Item 10.    Certification.      
   By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.      

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 11, 2010

 

ABINGWORTH MANAGEMENT LIMITED
By:  

/S/    JAMES ABELL        

Name:   James Abell
Title:   Executive Director
ABINGWORTH LLP
By:  

/S/    JAMES ABELL        

Name:   James Abell
Title:   Member

Exhibit 1

AGREEMENT

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Poniard Pharmaceuticals, Inc.

Date: February 11, 2010

 

ABINGWORTH MANAGEMENT LIMITED
By:  

/S/    JAMES ABELL        

Name:   James Abell
Title:   Executive Director
ABINGWORTH LLP
By:  

/S/    JAMES ABELL        

Name:   James Abell
Title:   Member
 -----END PRIVACY-ENHANCED MESSAGE-----